hers semaglutide ban Hims & stock falls 25% as FDA curtails compounded GLP-1s Novo Nordisk expands Wegovy access

Elevated inflammation and oxidative stress are intently related, and NAC shows anti-inflammatory and antioxidant effects

In December 2025, the World Health Organization (WHO) issued new guidelines recommending GLP-1 medications to help treat obesity

Hand 6 , 149158 (2011)

A Second Lawsuit Complicates the Narrative In the wake of Novo filing suit against Hims, consumer plaintiffs Andrew Donoho and Gloria Ferguson brought a separate case in an Illinois federal court alleging that Hims has misled purchasers by advertising its compounded semaglutide as having the same active ingredient as Ozempic and Wegovy. Unlike Novos patent case, the Illinois complaint does not hinge on whether Hims product contains semaglutide

Its been the first-line treatment for type 2 diabetes for decades

Diese Methode ist einfacher in der Handhabung, allerdings berichten Nutzer, dass die Wirkung im Vergleich zur Injektion schwcher oder weniger zuverlssig sein kann